Novel Advances in Pharma for NTDs:The case of Chemo Group and Mundo Sano Foundation

Novel Advances in Pharma for NTDs:The case of Chemo Group and Mundo Sano Foundation.

Mundo Sano Foundation (MS) channels the corporate social responsibility of the family owned pharmaceutical company: Chemo Group. Born in Argentina in 1993, MS starts its work on Neglected Tropical Diseases (NTDs) focusing on Chagas disease, one of the 17 NTDs named by the World Health Organization (WHO) in 2010, currently the list has been increased to include 20 diseases. Fruit of this collaboration, Chemo group developed in 2012 the drug of choice for Chagas disease, benznidazol. This decision was taken by the pharmaceutical group due to the world stock´s breakage of benznidazol which occurred in 2011, and thanks to MS intermediation. Nowadays and due to this drug development, Chemo group has obtained a Food and Drug Administration (FDA) Priority Review Voucher (PRV) in the United States of America (USA), which Chemo group has committed to invest 50% of the PRV total amount to NTD programs.

The amount of migrant population coming from Latin America to Spain since the last decades of the 20th century, has converted Spain in the second non endemic country, after USA, with the highest amount of population affected by Chagas disease in the world. According to different estimations, there may be between 50,000 and 100,000 people living with Chagas disease in Spain at the moment. In 2010, MS started its program in Spain with the compromise to fight Chagas disease with a global vision.

KEYWORDS & TOPICS

Neglected Tropical Diseases (NTDs); Corporate Social Responsibility (CSR); Priority Review Voucher (PRV); Food and Drug Administration (FDA) ; Chagas disease; benznidazol; Soil Transmited Helmints (STH); Ivermectine; Albendazol; coformulation.